1-(2-Aminophenyl)ethanone: Essential Intermediate for Pharmaceutical R&D
In the demanding landscape of pharmaceutical research and development (R&D), the availability of high-quality, reliable chemical intermediates is paramount. 1-(2-Aminophenyl)ethanone, identified by CAS number 551-93-9, is one such compound that plays a crucial role in the synthesis of novel drug candidates and the optimization of existing pharmaceutical processes. For R&D scientists and procurement specialists, understanding the significance and sourcing of this versatile molecule is key to driving innovation forward.
The Importance of 1-(2-Aminophenyl)ethanone in Drug Discovery
1-(2-Aminophenyl)ethanone serves as a fundamental building block in the synthetic chemist's toolkit, particularly within the pharmaceutical industry. Its unique molecular structure, featuring an ortho-substituted aminoketone, makes it an ideal precursor for creating a wide array of heterocyclic compounds, which are common motifs in many FDA-approved drugs. Researchers frequently purchase this intermediate to construct complex molecular architectures, explore new pharmacophores, and develop lead compounds in drug discovery programs. The ability to reliably synthesize these complex molecules often hinges on the purity and consistent quality of the starting materials. Therefore, sourcing 1-(2-Aminophenyl)ethanone from a reputable manufacturer who guarantees high purity is essential for reproducible and successful R&D outcomes.
Key Properties and Handling Considerations
1-(2-Aminophenyl)ethanone is typically described as a dark yellow to brown viscous liquid. While its physical properties are important for handling, its chemical reactivity is what makes it so valuable for synthesis. It participates readily in reactions characteristic of both amines and ketones. Standard laboratory safety precautions should always be observed when handling this chemical, including wearing appropriate personal protective equipment (PPE) such as gloves, safety glasses, and lab coats, and working in a well-ventilated area or fume hood. Understanding these handling requirements is part of the due diligence when you plan to buy this compound for your laboratory.
Sourcing Strategies for R&D Professionals
For R&D departments, ensuring a consistent and reliable supply of specialized chemicals like 1-(2-Aminophenyl)ethanone is critical to maintaining project momentum. When seeking to buy this intermediate, it is advisable to work with suppliers who cater specifically to the R&D sector, often offering smaller quantities suitable for laboratory use, along with detailed technical data. We, as a dedicated manufacturer and supplier, understand the unique needs of R&D professionals. We provide high-purity 1-(2-Aminophenyl)ethanone and are available to offer quotes and technical support to facilitate your research projects. Partnering with a global supplier can also ensure access to materials even during regional shortages.
Conclusion: A Vital Component for Innovation
In summary, 1-(2-Aminophenyl)ethanone is a cornerstone intermediate for pharmaceutical R&D, enabling the synthesis of diverse and complex molecular structures vital for new drug development. By prioritizing suppliers that offer high purity and reliable service, research institutions and pharmaceutical companies can effectively secure this essential compound. If you are looking to buy 1-(2-Aminophenyl)ethanone for your R&D efforts, consider our commitment to quality and our capabilities as a trusted manufacturer and supplier.
Perspectives & Insights
Data Seeker X
“If you are looking to buy 1-(2-Aminophenyl)ethanone for your R&D efforts, consider our commitment to quality and our capabilities as a trusted manufacturer and supplier.”
Chem Reader AI
“In the demanding landscape of pharmaceutical research and development (R&D), the availability of high-quality, reliable chemical intermediates is paramount.”
Agile Vision 2025
“1-(2-Aminophenyl)ethanone, identified by CAS number 551-93-9, is one such compound that plays a crucial role in the synthesis of novel drug candidates and the optimization of existing pharmaceutical processes.”